BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 32011527)

  • 1. Intratumoral Fibrosis and Tumor Growth Pattern as Prognostic Factors in Optimally Resected Pancreatic Neuroendocrine Neoplasms: An Analysis of 168 Cases.
    Chatterjee D; Trikalinos NA; Williams GA; Liu J; Hawkins WG; Hammill C
    Pancreas; 2020 Feb; 49(2):255-260. PubMed ID: 32011527
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Accuracy of Grading in Pancreatic Neuroendocrine Neoplasms and Effect on Survival Estimates: An Institutional Experience.
    Trikalinos NA; Chatterjee D; Lee J; Liu J; Williams G; Hawkins W; Hammill C
    Ann Surg Oncol; 2020 Sep; 27(9):3542-3550. PubMed ID: 32206954
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictors of Recurrence and Survival in Patients With Surgically Resected Pancreatic Neuroendocrine Tumors.
    Rosenblum RE; Harris CK; Baeg KJ; Starr JA; Brais LK; Stashek KM; Ward SC; Katona BW; Clancy TE; Wisnivesky JP; Kulke MH; Metz DC; Kim MK; Chan JA
    Pancreas; 2020 Feb; 49(2):249-254. PubMed ID: 32011530
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Operative resection in early stage pancreatic neuroendocrine tumors in the United States: Are we over- or undertreating patients?
    Chivukula SV; Tierney JF; Hertl M; Poirier J; Keutgen XM
    Surgery; 2020 Jan; 167(1):180-186. PubMed ID: 31537303
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of risk factors for recurrence after curative resection of well-differentiated pancreatic neuroendocrine tumors based on the new grading classification.
    Tsutsumi K; Ohtsuka T; Fujino M; Nakashima H; Aishima S; Ueda J; Takahata S; Nakamura M; Oda Y; Tanaka M
    J Hepatobiliary Pancreat Sci; 2014 Jun; 21(6):418-25. PubMed ID: 24142395
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Venous invasion and lymphatic invasion are correlated with the postoperative prognosis of pancreatic neuroendocrine neoplasm.
    Kiritani S; Arita J; Mihara Y; Nagata R; Ichida A; Kawaguchi Y; Ishizawa T; Akamatsu N; Kaneko J; Hasegawa K
    Surgery; 2023 Feb; 173(2):365-372. PubMed ID: 36123176
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic value of CT findings to predict survival outcomes in patients with pancreatic neuroendocrine neoplasms: a single institutional study of 161 patients.
    Kim DW; Kim HJ; Kim KW; Byun JH; Kim SY; Song KB; Ramaiya NH; Tirumani SH; Hong SM
    Eur Radiol; 2016 May; 26(5):1320-9. PubMed ID: 26253259
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Infiltrative Growth Predicts the Risk of Recurrence After Surgery in Well-Differentiated Non-Functioning Pancreatic Neuroendocrine Tumors.
    Schiavo Lena M; Partelli S; Andreasi V; Muffatti F; Redegalli M; Brunetto E; Maghini B; Falke M; Cangi MG; Perren A; Falconi M; Doglioni C
    Endocr Pathol; 2023 Mar; 34(1):142-155. PubMed ID: 36564582
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of Outcomes Following Surgery for Locally Advanced Pancreatic Neuroendocrine Tumors.
    Titan AL; Norton JA; Fisher AT; Foster DS; Harris EJ; Worhunsky DJ; Worth PJ; Dua MM; Visser BC; Poultsides GA; Longaker MT; Jensen RT
    JAMA Netw Open; 2020 Nov; 3(11):e2024318. PubMed ID: 33146734
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relapse-free survival in patients with nonmetastatic, surgically resected pancreatic neuroendocrine tumors: an analysis of the AJCC and ENETS staging classifications.
    Strosberg JR; Cheema A; Weber JM; Ghayouri M; Han G; Hodul PJ; Kvols LK
    Ann Surg; 2012 Aug; 256(2):321-5. PubMed ID: 22415420
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Redefining the Ki-67 Index Stratification for Low-Grade Pancreatic Neuroendocrine Tumors: Improving Its Prognostic Value for Recurrence of Disease.
    Lopez-Aguiar AG; Ethun CG; Postlewait LM; Zhelnin K; Krasinskas A; El-Rayes BF; Russell MC; Sarmiento JM; Kooby DA; Staley CA; Maithel SK; Cardona K
    Ann Surg Oncol; 2018 Jan; 25(1):290-298. PubMed ID: 29079920
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Resection strategies for neuroendocrine pancreatic neoplasms.
    Watzka FM; Laumen C; Fottner C; Weber MM; Schad A; Lang H; Musholt TJ
    Langenbecks Arch Surg; 2013 Mar; 398(3):431-40. PubMed ID: 23143147
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumour grade and primary site predict patterns of recurrence and survival in patients with resected gastroenteropancreatic neuroendocrine tumors.
    Watanabe A; Yip L; Hamilton TD; Loree JM; Stuart HC
    Am J Surg; 2021 Jun; 221(6):1141-1149. PubMed ID: 33795127
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Surgical therapy of pancreatic cancer - 5 years survival].
    Loveček M; Skalický P; Klos D; Neoral Č; Ehrmann J; Zapletalová J; Švébišová H; Yogeswara T; Ghothim M; Vrba R; Havlík R
    Rozhl Chir; 2015 Nov; 94(11):470-6. PubMed ID: 26766155
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic impact of tumour burden in stage IV neuroendocrine neoplasia: A comparison between pancreatic and gastrointestinal localizations.
    Panzuto F; Pusceddu S; Faggiano A; Rinzivillo M; Brighi N; Prinzi N; Riccardi F; Iannicelli E; Maggio I; Femia D; Tafuto S; Manuzzi L; Di Sarno A; Annibale B; de Braud F; Campana D;
    Pancreatology; 2019 Dec; 19(8):1067-1073. PubMed ID: 31587962
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Machine learning-based model for prediction and feature analysis of recurrence in pancreatic neuroendocrine tumors G1/G2.
    Murakami M; Fujimori N; Nakata K; Nakamura M; Hashimoto S; Kurahara H; Nishihara K; Abe T; Hashigo S; Kugiyama N; Ozawa E; Okamoto K; Ishida Y; Okano K; Takaki R; Shimamatsu Y; Ito T; Miki M; Oza N; Yamaguchi D; Yamamoto H; Takedomi H; Kawabe K; Akashi T; Miyahara K; Ohuchida J; Ogura Y; Nakashima Y; Ueki T; Ishigami K; Umakoshi H; Ueda K; Oono T; Ogawa Y
    J Gastroenterol; 2023 Jun; 58(6):586-597. PubMed ID: 37099152
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metastatic Risk in Pancreatic Neuroendocrine Tumors: An 18-Year Experience From Bogotá, Colombia-A Case Series.
    Guzmán Ruiz YF; González Devia D; Vera Torres A; López Panqueva RDP; Ardila Duarte G
    Pancreas; 2020 Sep; 49(8):e68-e70. PubMed ID: 32833947
    [No Abstract]   [Full Text] [Related]  

  • 18. MRI-based nomogram estimates the risk of recurrence of primary nonmetastatic pancreatic neuroendocrine tumors after curative resection.
    Sun HT; Zhang SL; Liu K; Zhou JJ; Wang XX; Shen TT; Song XH; Guo YL; Wang XL
    J Magn Reson Imaging; 2019 Aug; 50(2):397-409. PubMed ID: 30589158
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of recurrence after resection of well-differentiated non-functioning pancreatic neuroendocrine tumors.
    Tan QQ; Wang X; Yang L; Chen YH; Tan CL; Zhu XM; Ke NW; Liu XB
    Medicine (Baltimore); 2020 Jun; 99(24):e20324. PubMed ID: 32541455
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel recurrence risk stratification of resected pancreatic neuroendocrine tumor.
    Gao H; Liu L; Wang W; Xu H; Jin K; Wu C; Qi Z; Zhang S; Liu C; Xu J; Ni Q; Yu X
    Cancer Lett; 2018 Jan; 412():188-193. PubMed ID: 29107104
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.